Lyell Immunopharma to Participate in Upcoming Investor Conferences
2023年9月1日 - 5:05AM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, today announced that
members of its senior management team will participate in the
following upcoming healthcare conferences:
- Morgan Stanley 21st Annual
Global Healthcare Conference
- Monday, September 11, 4:55 p.m.
ET
- H.C. Wainwright 25th Annual
Global Investment Conference
- Tuesday, September 12th, 9:00 a.m.
ET
- 2023 Cantor Global
Healthcare Conference
- Wednesday, September 27th at
3:35 p.m. ET
Live webcasts of the presentations can be
accessed through the investor relations section of the Company's
website at www.lyell.com. Following the live presentations, a
replay of the webcast will be available on the Company's website
for 90 days following the presentation date.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. Lyell is currently enrolling a Phase 1 clinical
trial evaluating a ROR1-targeted CAR T-cell therapy in patients
with relapsed refractory triple-negative breast cancer and
non-small cell lung cancer (NSCLC) and a second Phase 1 clinical
trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL)
in patients with advanced melanoma, NSCLC and colorectal cancer.
The technologies powering its product candidates are designed to
address barriers that limit consistent and long-lasting responses
to cell therapy for solid tumors: T-cell exhaustion and lack of
durable stemness, which includes the ability to persist and
self-renew to drive durable tumor cytotoxicity. Lyell is applying
its proprietary ex vivo genetic and epigenetic reprogramming
technologies to address these barriers in order to develop new
medicines with improved durable clinical outcomes. Lyell is based
in South San Francisco, California with facilities in Seattle and
Bothell, Washington. To learn more, please visit www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
過去 株価チャート
から 4 2024 まで 5 2024
Lyell Immunopharma (NASDAQ:LYEL)
過去 株価チャート
から 5 2023 まで 5 2024